Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study of the Effects of Eculizumab in CD59 Deficiency

Next Previous
Trial Profile

An Open Label Study of the Effects of Eculizumab in CD59 Deficiency

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Haemolysis
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 06 Dec 2016 Results of this and one other study presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 18 Oct 2016 New trial record
    • 29 Aug 2016 According to the results published in the Annals of Neurology, the study was initially designed to include 8 months of eculizumab treatment. After 8 months the study seemed to be life saving and hence was extended to 2 years
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top